Xiuning Le, MD, PhD, discusses the emergence of antibody-drug conjugates in non–small cell lung cancer.
Xiuning Le, MD, PhD
Advertisement
Xiuning Le, MD, PhD, is an associate professor in the Department of Thoracic/Head and Neck Medical Oncology in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center
Articles by Xiuning Le, MD, PhD
Xiuning Le, MD, PhD, discusses next steps with poziotinib (NOV120101, HM781-36B) in patients with EGFR-positive or HER2-positive exon 20–mutant non–small cell lung cancer.
Xiuning Le, MD, PhD, discusses the safety findings of the phase 2 ZENITH20-5 study with poziotinib in patients with EGFR- or HER2 exon 20–positive non–small cell lung cancer.
Xiuning Le, MD, PhD, discusses the design of the phase 2 VISION trial in MET exon 14 skipping—mutant non–small cell lung cancer.
Xiuning Le, MD, PhD, discusses the rationale for tepotinib in MET exon 14 skipping
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
As ADC Options Expand, Sequencing and Toxicity Management Become the Next Challenges in Gynecologic Oncology
3
MANGROVE Trial Shows Improved Efficacy With Zanubrutinib Plus Rituximab vs Chemo in MCL
4
Experts Outline the Evolving Role of ctDNA-Based MRD Testing Across Solid Tumors
5